EDIT
Price
$10.53
Change
+$0.47 (+4.67%)
Updated
Mar 1, 6:59 PM EST
60 days until earnings call
MDGL
Price
$251.63
Change
+$15.43 (+6.53%)
Updated
Mar 1, 6:59 PM EST
66 days until earnings call
Ad is loading...

EDIT vs MDGL ᐉ Comparison: Which is Better to Invest?

Header iconEDIT vs MDGL Comparison
Open Charts EDIT vs MDGLBanner chart's image
Editas Medicine
Price$10.53
Change+$0.47 (+4.67%)
Volume$1.61M
CapitalizationN/A
Madrigal Pharmaceuticals
Price$251.63
Change+$15.43 (+6.53%)
Volume$176.08K
CapitalizationN/A
View a ticker or compare two or three
EDIT vs MDGL Comparison Chart

Loading...

EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EDIT vs. MDGL commentary
Mar 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and MDGL is a Buy.

COMPARISON
Comparison
Mar 02, 2024
Stock price -- (EDIT: $10.53 vs. MDGL: $251.63)
Brand notoriety: EDIT and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 95% vs. MDGL: 38%
Market capitalization -- EDIT: $821.64M vs. MDGL: $4.66B
EDIT [@Biotechnology] is valued at $821.64M. MDGL’s [@Biotechnology] market capitalization is $4.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, both EDIT and MDGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 7 bullish TA indicator(s).

  • EDIT’s TA Score: 5 bullish, 6 bearish.
  • MDGL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +34.83% price change this week, while MDGL (@Biotechnology) price change was +6.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was +20.20%, and the average quarterly price growth was +48.09%.

Reported Earning Dates

EDIT is expected to report earnings on May 01, 2024.

MDGL is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($4.66B) has a higher market cap than EDIT($822M). MDGL YTD gains are higher at: 8.752 vs. EDIT (3.949). EDIT has higher annual earnings (EBITDA): -202.49M vs. MDGL (-336.4M). EDIT has more cash in the bank: 350M vs. MDGL (232M). EDIT has less debt than MDGL: EDIT (34.6M) vs MDGL (117M). EDIT has higher revenues than MDGL: EDIT (24.6M) vs MDGL (0).
EDITMDGLEDIT / MDGL
Capitalization822M4.66B18%
EBITDA-202.49M-336.4M60%
Gain YTD3.9498.75245%
P/E RatioN/AN/A-
Revenue24.6M0-
Total Cash350M232M151%
Total Debt34.6M117M30%
FUNDAMENTALS RATINGS
EDIT vs MDGL: Fundamental Ratings
EDIT
MDGL
OUTLOOK RATING
1..100
4062
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for MDGL (96) in the Pharmaceuticals Other industry. This means that EDIT’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that EDIT’s stock grew similarly to MDGL’s over the last 12 months.

EDIT's Price Growth Rating (50) in the Biotechnology industry is in the same range as MDGL (50) in the Pharmaceuticals Other industry. This means that EDIT’s stock grew similarly to MDGL’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that EDIT’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITMDGL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 5 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRCOX49.68N/A
N/A
T. Rowe Price U.S. Equity Research R
VLCGX20.52N/A
N/A
VALIC Company I Large Capital Growth
HILVX22.61N/A
N/A
Harbor Large Cap Value Inv
UMPSX47.48N/A
N/A
ProFunds UltraMid Cap Svc
LBWCX19.43N/A
N/A
BrandywineGLOBAL Div US Large Value C